Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Active, not recruiting · NCT04448886 · Registry updated 2026-01-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-01-15 | NCT04448886 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ana C Garrido-Castro, MD | 2 |
| Gilead Sciences | 180 |
| Merck Sharp & Dohme LLC | 650 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| DF/BWCC in clinical affiliation with South Shore Hospital | South Weymouth | United States | 5 |
| DFCI @ Foxborough | Foxborough | United States | 3 |
| DFCI @ Milford Regional Hospital | Milford | United States | 3 |
| Emory University/Winship Cancer Institute | Atlanta | United States | 14 |
| University of Chicago Medical Center | Chicago | United States | 152 |
| University of North Carolina at Chapel Hill | Chapel Hill | United States | 129 |
| University of Pennsylvania-Abramson Cancer Center | Philadelphia | United States | 3 |